Compare ImmunityBio Inc. Common Stock (IBRX) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Shell PLC — how do they compare? ImmunityBio Inc. Common Stock trades at $10.01 (market cap $10.33B), while Shell PLC trades at $99.72 (market cap $275.54B). The key difference: Shell PLC is far larger — about 26.7× ImmunityBio Inc. Common Stock's market cap, and Shell PLC pays a 3.23% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Shell PLC for 90 Days on average.
| IBRX | SHEL | |
|---|---|---|
Market Cap | $10.33B | $275.54B |
Volume | 11,745,198 | 4,925,662 |
Sector | Health | Energy |
52-Week High | $11.55 | $100.20 |
52-Week Low | $1.98 | $70.31 |
Typical Hold Time | 0 Days | 90 Days |
Enterprise Value | $10.79B | $317.24B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Shell (SHEL) trades at $100.20, up 2.64% today, approaching its 52-week high with strong technical momentum. The stock shows solid fundamentals with a P/E of 10.71 and net income margin of 8.76%, supported by recent earnings beats. Recent developments include the LNG Canada Phase 2 expansion approval, doubling export capacity to 28 million metric tons annually, positioning Shell for long-term growth in global LNG markets.
Outlook remains positive with analyst consensus at Buy (61.5%) and $102.53 price target. Key opportunities include LNG expansion and portfolio optimization, while risks involve energy price volatility and execution of major projects. The current valuation appears reasonable given strong cash flow generation and strategic positioning in transitional energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
